company background image
BCAR

Biocartis Group ENXTBR:BCART Stock Report

Last Price

€1.72

Market Cap

€98.9m

7D

-0.1%

1Y

-57.1%

Updated

07 Aug, 2022

Data

Company Financials +
BCART fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health1/6
Dividends0/6

BCART Stock Overview

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology.

Biocartis Group NV Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Biocartis Group
Historical stock prices
Current Share Price€1.72
52 Week High€4.38
52 Week Low€1.67
Beta1.54
1 Month Change-4.98%
3 Month Change-7.83%
1 Year Change-57.05%
3 Year Change-82.99%
5 Year Change-82.54%
Change since IPO-86.79%

Recent News & Updates

Shareholder Returns

BCARTBE Medical EquipmentBE Market
7D-0.1%-0.2%-0.6%
1Y-57.1%-22.7%-8.1%

Return vs Industry: BCART underperformed the Belgian Medical Equipment industry which returned -22.7% over the past year.

Return vs Market: BCART underperformed the Belgian Market which returned -8.1% over the past year.

Price Volatility

Is BCART's price volatile compared to industry and market?
BCART volatility
BCART Average Weekly Movement6.4%
Medical Equipment Industry Average Movement7.1%
Market Average Movement4.7%
10% most volatile stocks in BE Market8.4%
10% least volatile stocks in BE Market2.7%

Stable Share Price: BCART is more volatile than 75% of Belgian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BCART's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Belgian stocks.

About the Company

FoundedEmployeesCEOWebsite
2007619Herman Verrelsthttps://www.biocartis.com

Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test.

Biocartis Group NV Fundamentals Summary

How do Biocartis Group's earnings and revenue compare to its market cap?
BCART fundamental statistics
Market Cap€98.86m
Earnings (TTM)-€71.47m
Revenue (TTM)€54.90m

1.8x

P/S Ratio

-1.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BCART income statement (TTM)
Revenue€54.90m
Cost of Revenue€80.61m
Gross Profit-€25.72m
Other Expenses€45.76m
Earnings-€71.47m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 01, 2022

Earnings per share (EPS)-1.24
Gross Margin-46.84%
Net Profit Margin-130.19%
Debt/Equity Ratio-395.8%

How did BCART perform over the long term?

See historical performance and comparison